- Home
- OABI vs AUTL Comparison
OABI vs AUTL Comparison
Compare OABI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | AUTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | 89 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.4M | 388.6M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | OABI | AUTL |
|---|---|---|
| Price | $2.32 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.50 | ★ $8.50 |
| AVG Volume (30 Days) | 562.9K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $52.42 | $80.32 |
| Revenue Next Year | $64.69 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.32 | $1.18 |
| 52 Week High | $2.79 | $2.70 |
Technical Indicators
Market Signals| Indicator | OABI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 52.46 |
| Support Level | $1.75 | $1.38 |
| Resistance Level | $2.70 | $1.73 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 54.91 | 61.54 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.